EGFR (Ab-1092) Antibody

What is EGFR (Ab-1092) Antibody and what epitope does it recognize?

EGFR (Ab-1092) Antibody is a rabbit polyclonal antibody that specifically recognizes the peptide sequence around amino acids 1090-1094 (P-E-Y-I-N) of human EGFR protein. The antibody is produced by immunizing rabbits with a synthetic non-phosphopeptide derived from human EGFR around the phosphorylation site of tyrosine 1092, then purified via affinity chromatography using epitope-specific immunogen . This antibody detects endogenous levels of total EGFR protein regardless of its phosphorylation status, making it valuable for studying total EGFR expression levels in experimental systems .

What are the validated research applications for EGFR (Ab-1092) Antibody?

The primary validated applications for EGFR (Ab-1092) Antibody include Western blotting (WB) at a recommended dilution of 1:1000 and immunohistochemistry (IHC) . The antibody has demonstrated reactivity with human and rat samples, making it suitable for comparative studies across these species . Western blot analysis using this antibody can detect the approximately 170 kDa EGFR protein in cell extracts from various sources, including HUVEC cells as demonstrated in validation studies .

How does EGFR (Ab-1092) Antibody differ from phospho-specific EGFR antibodies?

EGFR (Ab-1092) Antibody recognizes total EGFR protein regardless of phosphorylation status, whereas phospho-specific antibodies such as those targeting phospho-Tyr1092 only detect EGFR when phosphorylated at specific residues . This distinction is critical for experimental design, as using both types of antibodies in parallel can provide insights into both expression levels and activation status of EGFR. Western blot analysis comparing EGFR (Ab-1092) with phospho-Tyr1092 antibodies demonstrates their complementary nature, where the former shows consistent bands with or without EGF stimulation, while the latter shows bands only in EGF-stimulated samples .

What are the optimal sample preparation protocols for EGFR (Ab-1092) Antibody in Western blotting?

For optimal Western blotting results with EGFR (Ab-1092) Antibody, researchers should prepare cell lysates using a buffer containing protease inhibitors to prevent EGFR degradation. Samples should be denatured at 95°C for 5 minutes in Laemmli buffer containing SDS and a reducing agent. When working with membrane proteins like EGFR, it's essential to avoid excessive heating that might cause protein aggregation . For maximum sensitivity, loading 20-50 μg of total protein per lane is recommended, and proteins should be transferred to PVDF membrane rather than nitrocellulose, as the former shows better retention of high molecular weight proteins like EGFR .

How can researchers design experiments to simultaneously evaluate EGFR expression and phosphorylation status?

A comprehensive experimental approach to evaluate both EGFR expression and activation requires parallel analysis with both EGFR (Ab-1092) and phospho-specific antibodies. The recommended methodology involves:

• Dividing samples and running identical gels

• Probing one membrane with EGFR (Ab-1092) to detect total EGFR

• Probing the other with phospho-Tyr1092 antibody to detect activated EGFR

• Normalizing phospho-EGFR signal to total EGFR signal to accurately assess activation levels

This approach allows quantification of the proportion of phosphorylated EGFR relative to total EGFR expression, providing a more accurate measure of receptor activation than either antibody alone .

What are the appropriate positive and negative controls for validating EGFR (Ab-1092) Antibody specificity?

To rigorously validate EGFR (Ab-1092) Antibody specificity, researchers should implement several controls:

Positive Controls:

• Cell lines with known high EGFR expression (e.g., A431 epidermoid carcinoma cells)

• EGF-stimulated cells showing increased EGFR levels

• Recombinant EGFR protein as a Western blot standard

Negative Controls:

• EGFR knockout/knockdown cells

• Peptide competition assay using the immunizing peptide

• Secondary antibody-only controls to assess non-specific binding

Additionally, a critical validation experiment involves comparing the staining pattern obtained with EGFR (Ab-1092) Antibody to that obtained with other well-characterized EGFR antibodies targeting different epitopes .

How does phosphorylation at Tyr1092 affect EGFR-mediated signaling cascades?

Phosphorylation at Tyr1092 (also referred to as Tyr1068 in some numbering systems) plays a crucial role in EGFR-mediated signaling by creating a docking site for the adaptor protein GRB2, which subsequently activates the RAS-RAF-MEK-ERK pathway . When EGFR binds its ligands (including EGF, TGF-α, and others), it undergoes homo- or heterodimerization followed by autophosphorylation at multiple tyrosine residues, including Tyr1092 . This phosphorylation event is particularly important for cell proliferation and survival signaling.

Unlike phosphorylation at Ser991 and Tyr998, which primarily regulate receptor endocytosis, phosphorylation at Tyr1092 is directly involved in downstream signaling cascade activation . Experimental studies have shown that mutations preventing phosphorylation at Tyr1092 significantly impair ERK activation and cell proliferation, highlighting its central role in EGFR signaling .

What is the relationship between EGFR heterodimerization and receptor phosphorylation?

EGFR heterodimerization with other ErbB family members, particularly HER2, significantly impacts receptor phosphorylation patterns and downstream signaling outcomes. Recent research demonstrates that:

• EGFR/HER2 heterodimers show distinct phosphorylation profiles compared to EGFR homodimers

• Heterodimerization can alter the accessibility of certain phosphorylation sites, including Tyr1092

• The balance between homo- and heterodimerization affects receptor internalization and recycling dynamics

In contexts with elevated EGFR expression, there is increased formation of EGFR/HER2 heterodimers, which can suppress internalization of HER2-targeted antibody-drug conjugates (ADCs) like T-DXd . This mechanism represents a significant pathway for resistance to HER2-targeted therapies, where phosphorylation status of various EGFR residues, including Tyr1092, may serve as biomarkers for predicting treatment response .

How do different EGFR phosphorylation sites coordinate to regulate receptor trafficking and signaling?

EGFR trafficking and signaling involve coordinated phosphorylation events at multiple sites, creating a complex regulatory network:

Research using phosphorylation-deficient mutants demonstrates that sites like Ser991 and Tyr998 are critical for receptor endocytosis but not for ERK signaling activation. When these sites are mutated, EGFR shows impaired internalization despite maintaining signaling capacity . Furthermore, the endocytosis-defective EGFR mutants exhibit elevated phosphorylation at positions Ser1039 and Thr1041, suggesting cross-talk between different phosphorylation sites and potential compensatory mechanisms .

How can EGFR (Ab-1092) Antibody be employed to investigate EGFR/HER2 heterodimerization in cancer models?

Investigating EGFR/HER2 heterodimerization requires sophisticated experimental approaches where EGFR (Ab-1092) Antibody serves as a valuable tool. A comprehensive methodology involves:

• Co-immunoprecipitation (Co-IP) studies:

  • Immunoprecipitate with EGFR (Ab-1092) Antibody

  • Probe for HER2 in the precipitated complex

  • Compare heterodimerization levels across different cell lines/conditions

• Proximity ligation assay (PLA):

  • Use EGFR (Ab-1092) Antibody in combination with HER2 antibodies

  • Quantify fluorescent spots indicating EGFR/HER2 proximity

  • Correlate with treatment response in patient-derived xenografts

Recent research has demonstrated that tumors with high EGFR/HER2 heterodimerization show reduced efficacy of HER2-targeted antibody-drug conjugates, as heterodimers affect receptor internalization dynamics . In colorectal cancer patient-derived xenografts with ERBB2 amplification, regions with reduced EGFR expression showed 2.6-fold reduction in EGFR/HER2 dimerization compared to EGFR-high regions, correlating with improved response to HER2-targeted therapies .

What methodologies can detect alterations in EGFR phosphorylation patterns in patient samples?

Detection of EGFR phosphorylation patterns in patient samples requires specialized techniques optimized for clinical specimens:

• Quantitative selected reaction monitoring (SRM) mass spectrometry:

  • Enables precise quantification of multiple phosphorylation sites simultaneously

  • Can be performed on FFPE tissue samples after protein extraction

  • Provides stoichiometric information on different phosphorylation events

• Multiplex immunofluorescence:

  • Combines EGFR (Ab-1092) Antibody with phospho-specific antibodies

  • Allows visualization of spatial heterogeneity in EGFR activation

  • Can correlate with treatment response zones within tumors

Clinical studies have indicated that EGFR expression levels may predict response to HER2-targeted therapies. In a multi-histology basket trial of trastuzumab emtansine (T-DM1), patients with progressive disease showed higher mean EGFR expression (407.7 amol/μg) compared to patients with better outcomes (204.1 amol/μg) . This suggests that assays measuring EGFR expression and phosphorylation status could serve as biomarkers for predicting treatment efficacy.

How can EGFR (Ab-1092) Antibody be utilized in studying resistance mechanisms to targeted therapies?

EGFR (Ab-1092) Antibody provides valuable insights into resistance mechanisms against targeted therapies through several experimental approaches:

• Temporal profiling of EGFR expression during treatment:

  • Monitor EGFR levels before, during, and after therapy

  • Correlate changes with emergence of resistance

  • Identify adaptive upregulation of EGFR as a resistance mechanism

• Comparative analysis of sensitive vs. resistant models:

  • Quantify EGFR expression and dimerization status

  • Assess correlation with therapy response

  • Identify potential combination strategies

Research has shown that elevated EGFR expression mediates resistance to HER2-targeted antibody-drug conjugates by promoting EGFR/HER2 heterodimerization and suppressing internalization of the therapeutic agent . This resistance mechanism can be overcome by combining HER2-targeted therapies with EGFR-directed antibodies, which restore HER2/ADC trafficking and enhance efficacy. In colorectal cancer patient-derived xenografts, the combination of T-DXd and cetuximab resulted in 73.59% better response than cetuximab alone and 43.65% better than T-DXd alone .

What are the common sources of variability in EGFR (Ab-1092) Antibody experiments and how can they be addressed?

Several factors can introduce variability in experiments using EGFR (Ab-1092) Antibody:

• Antibody storage and handling:

  • Store at -20°C for long-term preservation

  • Avoid repeated freeze-thaw cycles

  • Prepare working aliquots to maintain antibody integrity

• Sample preparation inconsistencies:

  • Standardize cell lysis protocols

  • Ensure complete solubilization of membrane proteins

  • Maintain consistent protein concentrations across experiments

• EGFR expression heterogeneity:

  • Account for intrinsic variability in EGFR expression

  • Use appropriate normalization controls

  • Consider cell density and growth conditions that affect EGFR levels

To address these issues, researchers should implement rigorous quality control measures, including standard curves with recombinant EGFR protein, consistent sample preparation protocols, and appropriate housekeeping gene controls for normalization .

How can researchers distinguish between specific and non-specific signals when using EGFR (Ab-1092) Antibody?

Distinguishing specific from non-specific signals requires systematic validation approaches:

• Peptide competition assays:

  • Pre-incubate EGFR (Ab-1092) Antibody with excess immunizing peptide

  • Specific signals should be blocked in peptide-competed samples

  • Non-specific signals will persist despite peptide competition

• Molecular weight verification:

  • EGFR should appear at approximately 170 kDa

  • Verify band position using positive control samples

  • Analyze multiple cell lines with varying EGFR expression levels

• siRNA/CRISPR validation:

  • Compare signals between EGFR knockdown/knockout and control samples

  • Specific signals should decrease proportionally to the reduction in EGFR expression

  • Use quantitative analysis to confirm correlation between band intensity and EGFR mRNA levels

These validation steps ensure that experimental observations reflect genuine EGFR biology rather than artifacts or cross-reactivity with other proteins .

What are the best practices for quantifying EGFR expression levels in heterogeneous tumor samples?

Quantifying EGFR in heterogeneous tumor samples presents unique challenges requiring specialized approaches:

• Tissue microarray analysis:

  • Use EGFR (Ab-1092) Antibody for immunohistochemistry on tissue microarrays

  • Employ digital pathology for quantitative scoring

  • Analyze multiple cores per tumor to account for heterogeneity

• Single-cell techniques:

  • Combine EGFR (Ab-1092) Antibody with single-cell protein analysis methods

  • Correlate EGFR expression with cell type markers

  • Map spatial distribution of EGFR expression within tumors

• Region-specific analysis:

  • Laser capture microdissection of distinct tumor regions

  • Quantify EGFR protein levels by Western blot or mass spectrometry

  • Correlate with regional treatment response patterns

Research on colorectal cancer patient-derived xenografts has revealed significant intratumoral heterogeneity in EGFR expression, with regions of reduced EGFR showing decreased EGFR/HER2 dimerization and potentially different treatment responses . This highlights the importance of region-specific analysis when evaluating EGFR expression as a biomarker for therapy selection.